Omega Pharma sells 24.04% interest in Arseus for between 8.00 euro and a maximum of 10.75 euro per share

 

Waregem (Belgium), 9 November 2009 (07:30 CET) – Omega Pharma NV, Arseus NV and Waterland Private Equity Investments (‘Waterland’) jointly announce today that Waterland has signed agreements to purchase a minority 25.10% interest in Arseus. Via its fourth fund, Waterland will purchase 7,500,000 shares (24.04%) from Omega Pharma and 330,000 shares (1.06%) from Couckinvest NV at 8.00 euro per Arseus share, plus an earn-out of up to 2.75 euro per share, payable when Waterland exits, depending on the future shareholder value created by Arseus. Completion of the transaction is scheduled for 25 November 2009.

 

Arseus, the former Professional Health Division of Omega Pharma, became an independent entity on 5 October 2007 via an IPO. After the IPO, Omega Pharma held 7,500,000 Arseus shares or 24.04% of the total shares in issue.

 

Based on the denominator of 31,195,121 (total number of shares) and the relevant notifications received by Arseus, the shareholding structure after completion of the transaction will be as follows:

 

 

 

Please open the link below for the full press release: